

Single-cell analyses reveal increased intratumoral heterogeneity and therapy resistance in small-cell lung cancer

Nature Cancer

1, 423-436

DOI: [10.1038/s43018-019-0020-z](https://doi.org/10.1038/s43018-019-0020-z)

Citation Report

#	ARTICLE	IF	CITATIONS
1	NOTCH Your Usual Suspect: MYC Charged with Controlling Neuroendocrine Cell-Fate in Small Cell Lung Cancer. <i>Cancer Cell</i> , 2020, 38, 17-20.	7.7	3
2	Nanomaterials for Diagnosis and Treatment of Brain Cancer: Recent Updates. <i>Chemosensors</i> , 2020, 8, 117.	1.8	107
3	A second Warburg-like effect in cancer metabolism: The metabolic shift of glutamine-derived nitrogen. <i>BioEssays</i> , 2020, 42, e2000169.	1.2	25
4	Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. <i>Molecular Cell</i> , 2020, 80, 562-577.	4.5	54
5	Identification of Mutations Related to Cisplatin-Resistance and Prognosis of Patients With Lung Adenocarcinoma. <i>Frontiers in Pharmacology</i> , 2020, 11, 572627.	1.6	9
6	The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1836-1843.	0.5	45
7	Fighting against Drug-Resistant Tumors using a Dual-Responsive Pt(IV)/Ru(II) Bimetallic Polymer. <i>Advanced Materials</i> , 2020, 32, e2004766.	11.1	89
8	<i>MYCN</i> drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity. <i>Genes and Development</i> , 2020, 34, 1210-1226.	2.7	46
9	Liquid Biopsy in Small Cell Lung Cancer – A Route to Improved Clinical Care?. <i>Cells</i> , 2020, 9, 2586.	1.8	3
10	MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. <i>Cancer Cell</i> , 2020, 38, 60-78.e12.	7.7	262
11	Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2814.	1.8	18
12	The therapy escapes of small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 374-375.	5.7	3
13	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a038240.	2.9	34
14	Exploration of Circulating Tumour Cell (CTC) Biology: A Paradigm Shift in Liquid Biopsy. <i>Indian Journal of Clinical Biochemistry</i> , 2021, 36, 131-142.	0.9	9
15	Clinical utility of circulating tumor cells: an update. <i>Molecular Oncology</i> , 2021, 15, 1647-1666.	2.1	101
16	Molecular mechanisms of YY1 overexpression in human cancers and its prognostic significance. , 2021, , 123-147.		0
18	The Interaction of the Senescent and Adjacent Breast Cancer Cells Promotes the Metastasis of Heterogeneous Breast Cancer Cells through Notch Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 849.	1.8	17
20	Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	33

#	ARTICLE	IF	CITATIONS
21	Spatial Epitope Barcoding Reveals Subclonal Tumor Patch Behaviors. SSRN Electronic Journal, 0, , .	0.4	2
22	Advances in novel molecular typing and precise treatment strategies for small cell lung cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 522-534.	0.7	8
23	Biological bases of cancer immunotherapy. Expert Reviews in Molecular Medicine, 2021, 23, e3.	1.6	14
24	Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability. Cells, 2021, 10, 337.	1.8	5
25	Developmental Insights into Lung Cancer. Annual Review of Cancer Biology, 2021, 5, 351-369.	2.3	5
26	Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discovery, 2021, 11, 1952-1969.	7.7	87
27	In silico optimization of cancer therapies with multiple types of nanoparticles applied at different times. Computer Methods and Programs in Biomedicine, 2021, 200, 105886.	2.6	9
28	Topological signatures in regulatory network enable phenotypic heterogeneity in small cell lung cancer. ELife, 2021, 10, .	2.8	42
29	Molecular profiles of small cell lung cancer subtypes: Therapeutic implications. Molecular Therapy - Oncolytics, 2021, 20, 470-483.	2.0	64
30	Small cell lung cancer enters the era of precision medicine. Cancer Cell, 2021, 39, 297-299.	7.7	31
31	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell, 2021, 39, 346-360.e7.	7.7	422
32	Neuroendocrine-Related Circulating Transcripts in Small-Cell Lung Cancers: Detection Methods and Future Perspectives. Cancers, 2021, 13, 1339.	1.7	3
33	A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, 531-540.	1.1	15
35	Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 656611.	1.3	4
36	Promising Role of Circulating Tumor Cells in the Management of SCLC. Cancers, 2021, 13, 2029.	1.7	7
37	Leveraging Single-Cell Approaches in Cancer Precision Medicine. Trends in Cancer, 2021, 7, 359-372.	3.8	18
38	Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes. Nature Communications, 2021, 12, 2048.	5.8	66
39	Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy. JTO Clinical and Research Reports, 2021, 2, 100164.	0.6	6

#	ARTICLE	IF	CITATIONS
41	Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis. <i>Cancers</i> , 2021, 13, 2265.	1.7	14
44	Liquid Biopsy Analysis of Circulating Tumor Biomarkers in Lung Cancer. , 0, , .		0
46	De novo deoxyribonucleotide biosynthesis regulates cell growth and tumor progression in small-cell lung carcinoma. <i>Scientific Reports</i> , 2021, 11, 13474.	1.6	4
47	Resveratrol reduces drug resistance of SCLC cells by suppressing the inflammatory microenvironment and the STAT3/VEGF pathway. <i>FEBS Open Bio</i> , 2021, 11, 2256-2265.	1.0	10
48	Reframing recalcitrance for small-cell lung cancer. <i>Annals of Oncology</i> , 2021, 32, 829-830.	0.6	1
49	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2â€“Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1821-1839.	0.5	34
50	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 757-766.	1.5	4
51	Overcoming Chemotherapy Resistance in SCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2002-2015.	0.5	39
53	Oxygen gradient and tumor heterogeneity: The chronicle of a toxic relationship. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188553.	3.3	17
54	Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion. <i>Advances in Therapy</i> , 2021, 38, 5431-5451.	1.3	12
55	Multi-level multi-modality (PET and CT) fusion radiomics: prognostic modeling for non-small cell lung carcinoma. <i>Physics in Medicine and Biology</i> , 2021, 66, 205017.	1.6	41
56	<i>Sox2</i> Is an Oncogenic Driver of Small-Cell Lung Cancer and Promotes the Classic Neuroendocrine Subtype. <i>Molecular Cancer Research</i> , 2021, 19, 2015-2025.	1.5	11
57	Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers. <i>Journal of Thoracic Oncology</i> , 2022, 17, 141-153.	0.5	53
58	Patient-Derived Xenografts to Study Cancer Metabolism: When Does X Mark the Spot?. <i>Cancer Research</i> , 2021, 81, 4399-4401.	0.4	0
59	SCLC-J1, a novel small cell lung cancer cell line. <i>Biochemistry and Biophysics Reports</i> , 2021, 27, 101089.	0.7	1
60	YAP drives fate conversion and chemoresistance of small cell lung cancer. <i>Science Advances</i> , 2021, 7, eabg1850.	4.7	52
61	Small-cell lung cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 3.	18.1	560
66	Mechanisms of small cell lung cancer metastasis. <i>EMBO Molecular Medicine</i> , 2021, 13, e13122.	3.3	102

#	ARTICLE	IF	CITATIONS
67	Circulating cancer stem cells: an interesting niche to explore. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 253-258.	0.5	4
69	Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers. Frontiers in Oncology, 2021, 11, 757323.	1.3	9
70	Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell, 2021, 39, 1479-1496.e18.	7.7	155
71	Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 744724.	1.3	15
72	Intratumor Heterogeneity in Hepatocellular Carcinoma: Challenges and Opportunities. Cancers, 2021, 13, 5524.	1.7	15
74	Lung Cancer Computational Biology and Resources. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a038273.	2.9	1
76	Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 391-400.	0.5	2
77	Recent advances in lung cancer genomics: Application in targeted therapy. Advances in Genetics, 2021, 108, 201-275.	0.8	5
78	Role of caveolin-1 as a biomarker for radiation resistance and tumor aggression in lung cancer. PLoS ONE, 2021, 16, e0258951.	1.1	11
79	Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. Nature Communications, 2021, 12, 6652.	5.8	14
80	TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change. Cell Reports, 2021, 37, 109979.	2.9	13
81	Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 476-481.	1.0	2
83	Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations. Cancer and Metastasis Reviews, 2021, 40, 1141-1157.	2.7	16
84	Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq data. Genome Medicine, 2021, 13, 187.	3.6	25
86	A Nanoarchitectonic Approach Enables Triple Modal Synergistic Therapies To Enhance Antitumor Effects. ACS Applied Materials & Interfaces, 2022, 14, 10001-10014.	4.0	42
87	Therapeutic modalities in small cell lung cancer: a paradigm shift after decades of quiescence. Expert Opinion on Pharmacotherapy, 2022, 23, 583-597.	0.9	0
88	Killing SCLC: insights into how to target a shapeshifting tumor. Genes and Development, 2022, 36, 241-258.	2.7	26
89	High <sc>mRNA</sc> expression of <sc>POU2F3</sc> in small cell lung cancer cell lines predicts the effect of lurbinectedin. Thoracic Cancer, 2022, 13, 1184-1192.	0.8	5

#	ARTICLE	IF	CITATIONS
90	Cancer progression as a learning process. <i>IScience</i> , 2022, 25, 103924.	1.9	8
91	Single-Cell Transcriptome Identifies Drug-Resistance Signature and Immunosuppressive Microenvironment in Metastatic Small Cell Lung Cancer. <i>Genetics & Genomics Next</i> , 2022, 3, .	0.8	5
92	Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives. <i>Frontiers in Oncology</i> , 2022, 12, 836891.	1.3	5
93	Circulating tumor cells in precision medicine: challenges and opportunities. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 378-391.	4.0	47
94	Small cell lung cancer: Subtypes and therapeutic implications. <i>Seminars in Cancer Biology</i> , 2022, 86, 543-554.	4.3	21
95	Dual Inhibition of H3K9me2 and H3K27me3 Promotes Tumor Cell Senescence without Triggering the Secretion of SASP. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3911.	1.8	4
96	Limited-Stage Small-Cell Lung Cancer: Current Progress and the Next Frontier. <i>Radiation</i> , 2021, 1, 317-333.	0.6	0
97	Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 669-682.	0.6	77
98	Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models. <i>Nature Communications</i> , 2022, 13, 2023.	5.8	36
99	Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. <i>British Journal of Cancer</i> , 2022, 127, 569-576.	2.9	8
104	Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 614-628.	5.7	14
105	KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming. <i>Nature Cancer</i> , 2022, 3, 753-767.	5.7	41
106	Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. <i>International Journal of Biological Sciences</i> , 2022, 18, 3019-3033.	2.6	54
107	Organoids as a Systems Platform for SCLC Brain Metastasis. <i>Frontiers in Oncology</i> , 2022, 12, 881989.	1.3	5
108	High-throughput single-Cell sequencing in cancer research. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 145.	7.1	39
109	The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 113064.	2.5	14
110	A conserved YAP/Notch/REST network controls the neuroendocrine cell fate in the lungs. <i>Nature Communications</i> , 2022, 13, 2690.	5.8	19
111	Circulating tumor cells in neuroblastoma: Current status and future perspectives. <i>Cancer Medicine</i> , 2023, 12, 7-19.	1.3	4

#	ARTICLE	IF	CITATIONS
112	Decoding Lung Cancer at Single-Cell Level. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
113	Comparative characteristics of small cell lung cancer and Ewing's sarcoma: a narrative review. <i>Translational Lung Cancer Research</i> , 2022, 11, 1185-1198.	1.3	4
114	From single-omics to interactomics: How can ligand-induced perturbations modulate single-cell phenotypes?. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, , .	1.0	1
115	Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell Lung Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1379-1390.	1.5	8
116	Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment. <i>Oncogene</i> , 2022, 41, 3511-3523.	2.6	10
117	Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. <i>Nature Biotechnology</i> , 2022, 40, 1624-1633.	9.4	31
118	Photoelectrochemical biosensing platforms for tumor marker detection. <i>Coordination Chemistry Reviews</i> , 2022, 469, 214675.	9.5	41
121	Mutant-Allele Tumor Heterogeneity, a Favorable Biomarker to Assess Intra-Tumor Heterogeneity, in Advanced Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
123	Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review. <i>Seminars in Cancer Biology</i> , 2022, 86, 521-542.	4.3	5
124	Emerging Biomarkers and the Changing Landscape of Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3772.	1.7	11
125	cfDNA methylome profiling for detection and subtyping of small cell lung cancers. <i>Nature Cancer</i> , 2022, 3, 1260-1270.	5.7	47
127	ASURAT: functional annotation-driven unsupervised clustering of single-cell transcriptomes. <i>Bioinformatics</i> , 2022, 38, 4330-4336.	1.8	2
128	Immunogenicity of small-cell lung cancer associates with STING pathway activation and is enhanced by ATR and TOP1 inhibition. <i>Cancer Medicine</i> , 2023, 12, 4864-4881.	1.3	8
129	Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer. <i>Cell Systems</i> , 2022, 13, 690-710.e17.	2.9	22
131	Single-cell transcriptomics of neuroblastoma identifies chemoresistance-associated genes and pathways. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4437-4445.	1.9	6
132	Chemotherapy for Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
133	Genomic and Gene Expression Studies Helped to Define the Heterogeneity of Small-Cell Lung Cancer and Other Lung Neuroendocrine Tumors and to Identify New Therapeutic Targets. <i>Onco</i> , 2022, 2, 186-244.	0.2	0
134	Accurate treatment of small cell lung cancer: Current progress, new challenges and expectations. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188798.	3.3	2

#	ARTICLE	IF	CITATIONS
136	Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies. <i>Cancer Science</i> , 2023, 114, 665-679.	1.7	3
137	Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes. <i>Communications Medicine</i> , 2022, 2, .	1.9	2
138	Analysis of Circulating Tumor and Cancer Stem Cells Provides New Opportunities in Diagnosis and Treatment of Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10853.	1.8	1
139	Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy. <i>Military Medical Research</i> , 2022, 9, .	1.9	19
140	Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	12
141	Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	22
142	Bibliometric analysis of global research trends on small-cell lung cancer (2012â€“2021). <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
143	Small-cell lung cancer brain metastasis: From molecular mechanisms to diagnosis and treatment. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166557.	1.8	17
146	Spatial epitope barcoding reveals clonal tumor patch behaviors. <i>Cancer Cell</i> , 2022, 40, 1423-1439.e11.	7.7	13
148	DLL3 regulates Notch signaling in small cell lung cancer. <i>IScience</i> , 2022, 25, 105603.	1.9	7
149	DNA barcoding reveals ongoing immunoeediting of clonal cancer populations during metastatic progression and immunotherapy response. <i>Nature Communications</i> , 2022, 13, .	5.8	6
150	Holistic immunomodulation for small cell lung cancer. <i>Seminars in Cancer Biology</i> , 2023, 88, 96-105.	4.3	4
151	Molecular profiles of single circulating tumor cells from early breast cancer patients with different lymph node statuses. <i>Thoracic Cancer</i> , 0, , .	0.8	4
152	An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC. <i>Journal of Thoracic Oncology</i> , 2023, 18, 350-368.	0.5	6
153	Molecular features and evolutionary trajectory of ASCL1+ and NEUROD1+ SCLC cells. <i>British Journal of Cancer</i> , 2023, 128, 748-759.	2.9	1
154	Technologies for Viable Circulating Tumor Cell Isolation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15979.	1.8	4
155	Multivalent state transitions shape the intratumoral composition of small cell lung carcinoma. <i>Science Advances</i> , 2022, 8, .	4.7	4
156	Near-Infrared Light-Responsive Size-Selective Lateral Flow Chip for Single-Cell Manipulation of Circulating Tumor Cells. <i>Analytical Chemistry</i> , 0, , .	3.2	0

#	ARTICLE	IF	CITATIONS
157	Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	9
158	Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer. <i>Modern Pathology</i> , 2023, 36, 100028.	2.9	3
159	Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2023, 159, 114248.	2.5	6
160	Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes. <i>Cancer Discovery</i> , 2023, 13, 928-949.	7.7	16
161	Involvement of Epithelial-Mesenchymal Transition Genes in Small Cell Lung Cancer Phenotypic Plasticity. <i>Cancers</i> , 2023, 15, 1477.	1.7	4
162	Combining atomic force microscopy with complementary techniques for multidimensional single-cell analysis. <i>Journal of Microscopy</i> , 2023, 290, 69-96.	0.8	2
163	The functional and clinical roles of liquid biopsy in patient-derived models. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	11
182	Circulating tumor cell-derived preclinical models: current status and future perspectives. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	2
186	State of the Art in the Propagation of Circulating Tumor Cells. <i>Current Cancer Research</i> , 2023, , 247-274.	0.2	0
187	Circulating Tumour Cell Isolation and Molecular Profiling; Potential Therapeutic Intervention. <i>Current Cancer Research</i> , 2023, , 359-385.	0.2	0